Next-generation AR therapies, such as abiraterone, enzalutamide, and apalutamide have significantly improved survival of men with castration-resistant prostate cancer, but resistance remains an issue (Beer et al., 2014, Ryan et al., 2013, Smith et al., 2018). The gene discussed is AR; the disease is prostate carcinoma.